Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OraProtect PLUS
- Development stage
- Unknown
- Lead developer
- Bioflag Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
OraProtect PLUS is a heat-killed probiotic combination product developed by Bioflag Biotech for the maintenance of oral health and immunity. The formulation consists of two specific inactivated bacterial strains: *Lactobacillus salivarius* subsp. *salicinius* AP-32 and *Lactobacillus paracasei* ET-66. Administered as an oral tablet, the product works by modulating the oral microbiota, specifically reducing the levels of the cariogenic pathogen *Streptococcus mutans* while promoting the growth of beneficial *Lactobacillus* and *Bifidobacterium* species. Additionally, it enhances the oral mucosal immune response by increasing the concentration of salivary secretory IgA. Clinical studies in healthy individuals have supported its efficacy in improving oral microbial balance and immune markers.
- Brand names
- OraProtect PLUS
- Other names
- heat-killed lactobacillus salivarius subsp. salicinius AP-32 + heat-killed lactobacillus paracasei ET-66inactivated L. salivarius AP-32 and L. paracasei ET-66AP-32 + ET-66
02
Targets
IgA (Immunoglobulin A)
Beyond the preview
Go deeper on OraProtect PLUS.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OraProtect PLUS.